Search Results

Press Releases

HUYABIO Presents Positive Phase 2 Data on HBI-8000 and Nivolumab Combination for Advanced Melanoma

November 8, 2024

·

4 min read

Press Releases

HUYABIO Validates Protective Mechanism for Antiarrhythmic Drug HBI-3000 in AF Patients, Paving the Way for a New Era in Atrial Fibrillation Treatment

November 15, 2024

·

3 min read

Drug Development

HUYABIO INTERNATIONAL ANNOUNCES INITIATION OF HBI-3000 PHASE 2 TRIAL

HUYABIO International today announced that the first three patients had been dosed in an ongoing Phase 2 study of HUYABIO’s novel drug for pharmacological cardioversion of atrial fibrillation (AF).

June 14, 2022

·

2 min read

HUYABIO INTERNATIONAL ANNOUNCES INITIATION OF PHASE 2 ATRIAL FIBRILLATION TRIAL

First patient dosed in trial investigating cardioversion of recent-onset atrial fibrillation [02-November-2021] SAN DIEGO , Nov. 2, 2021 /PRNewswire/ -- HUYABIO International (HUYABIO), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that the first patient has been dosed in a Phase 2 study of HUYABIO’s novel drug

November 2, 2021

·

3 min read

Biotech Beach

HUYABIO International Launches Hiyasta as Monotherapy for Adult T-cell Leukemia/Lymphoma in Japan

HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced the product launch in Japan for Hiyasta® tablets to treat relapsed and/or refractory (R/R) adult T-cell leukemia/lymphoma (ATLL).

October 19, 2021

·

2 min read

Policy

HUYABIO International Receives Regulatory Approval For Hiyasta® Monotherapy Of Peripheral T-Cell Lymphoma In Japan

HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced the regulatory approval of HBI-8000, brand name Hiyasta®, monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan.

November 30, 2021

·

2 min read

Policy

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan

Shenzhen Chipscreen Biosciences’ licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide (Tucidinostat, also known as Epidaza ®, Hiyasta®, HBI-8000) monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan.

December 1, 2021

·

3 min read

Business

Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma

HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that it had entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the combination of HUYABIO’s HBI-8000, an epigenetic immunomodifier, and Opdivo® (nivolumab), a PD-1 blocking antibody

March 30, 2021

·

2 min read

Policy

HUYABIO International Receives Regulatory Approval for HBI-8000 Monotherapy of Adult T-cell Leukemia/Lymphoma in Japan

HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced the regulatory approval for HBI-8000 monotherapy of relapsed or refractory (R/R) adult T-cell leukemia/lymphoma (ATL) by the Japanese Pharmaceuticals and Medical Devices Agency.

June 23, 2021

·

2 min read

Biotech Beach

HUYABIO Announces HBI-8000 Brand Name of Hiyasta™

HUYABIO International announced today that HBI-8000 will be marketed under the brand name Hiyasta ™ in Japan .

June 24, 2021

·

2 min read